- Home
- HUIZ vs SABS Comparison
HUIZ vs SABS Comparison
Compare HUIZ & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- SABS
- Stock Information
- Founded
- HUIZ 2006
- SABS 2014
- Country
- HUIZ China
- SABS United States
- Employees
- HUIZ N/A
- SABS N/A
- Industry
- HUIZ Specialty Insurers
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- HUIZ Finance
- SABS Health Care
- Exchange
- HUIZ Nasdaq
- SABS Nasdaq
- Market Cap
- HUIZ 29.1M
- SABS 23.9M
- IPO Year
- HUIZ 2020
- SABS N/A
- Fundamental
- Price
- HUIZ $3.74
- SABS $4.26
- Analyst Decision
- HUIZ
- SABS Strong Buy
- Analyst Count
- HUIZ 0
- SABS 5
- Target Price
- HUIZ N/A
- SABS $12.40
- AVG Volume (30 Days)
- HUIZ 302.1K
- SABS 94.9K
- Earning Date
- HUIZ 12-10-2024
- SABS 11-06-2024
- Dividend Yield
- HUIZ N/A
- SABS N/A
- EPS Growth
- HUIZ N/A
- SABS N/A
- EPS
- HUIZ 0.29
- SABS N/A
- Revenue
- HUIZ $170,927,079.00
- SABS $1,512,723.00
- Revenue This Year
- HUIZ N/A
- SABS N/A
- Revenue Next Year
- HUIZ $10.46
- SABS N/A
- P/E Ratio
- HUIZ $10.21
- SABS N/A
- Revenue Growth
- HUIZ N/A
- SABS N/A
- 52 Week Low
- HUIZ $0.43
- SABS $2.16
- 52 Week High
- HUIZ $10.58
- SABS $7.70
- Technical
- Relative Strength Index (RSI)
- HUIZ 58.54
- SABS 63.47
- Support Level
- HUIZ $2.60
- SABS $3.32
- Resistance Level
- HUIZ $3.06
- SABS $4.30
- Average True Range (ATR)
- HUIZ 0.94
- SABS 0.62
- MACD
- HUIZ 0.04
- SABS 0.07
- Stochastic Oscillator
- HUIZ 24.01
- SABS 84.07
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies who cooperate with the company, who the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.